GSK’s oncology and HIV drugs drive 7% sales rise in 2025
GSK has posted positive sales results for fiscal year 2025 (FY2025) as the company’s new CEO, Luke Miels, takes the …
Post
-
-
Eli Lilly soars past expectations to hit 45% sales growth in 2025
Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position …
-
Why pharma manufacturers are still investing in Europe
Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s share …
-
Novo Nordisk shares tumble 18% after 2026 sales dip warning
Shares in Novo Nordisk have plummeted after the drugmaker forecast a dip in sales and profit growth below analyst expectations …
-
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with …
-
CEPI and Samsung Biologics partner to boost global vaccine preparedness
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance …
-
Pfizer sets sights on R&D strategy amid modest FY25 results
New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company …
-
MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more …
-
Podcast: driving linked data insights, the complexities, and experiences
This is the final episode in season one of Insights Uncovered: A Real-World Data Podcast Series from GlobalData, presented by …
-
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic …
-
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment
Aquestive Therapeutics has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new …
-
Eli Lilly selects Pennsylvania for $3.5bn manufacturing site of obesity drugs
Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new …
-
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin. In a statement …
-
CHMP grants positive opinion for J&J’s Akeega use
Johnson & Johnson (J&J) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
-
CIRM unveils RAPID funding programme for rare diseases
The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and …
